These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

684 related items for PubMed ID: 31874110

  • 1. Suppression of the SLC7A11/glutathione axis causes synthetic lethality in KRAS-mutant lung adenocarcinoma.
    Hu K, Li K, Lv J, Feng J, Chen J, Wu H, Cheng F, Jiang W, Wang J, Pei H, Chiao PJ, Cai Z, Chen Y, Liu M, Pang X.
    J Clin Invest; 2020 Apr 01; 130(4):1752-1766. PubMed ID: 31874110
    [Abstract] [Full Text] [Related]

  • 2. Inhibition of DDR1 enhances in vivo chemosensitivity in KRAS-mutant lung adenocarcinoma.
    Nokin MJ, Darbo E, Travert C, Drogat B, Lacouture A, San José S, Cabrera N, Turcq B, Prouzet-Mauleon V, Falcone M, Villanueva A, Wang H, Herfs M, Mosteiro M, Jänne PA, Pujol JL, Maraver A, Barbacid M, Nadal E, Santamaría D, Ambrogio C.
    JCI Insight; 2020 Aug 06; 5(15):. PubMed ID: 32759499
    [Abstract] [Full Text] [Related]

  • 3. LKB1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in KRAS-Mutant Lung Adenocarcinoma.
    Galan-Cobo A, Sitthideatphaiboon P, Qu X, Poteete A, Pisegna MA, Tong P, Chen PH, Boroughs LK, Rodriguez MLM, Zhang W, Parlati F, Wang J, Gandhi V, Skoulidis F, DeBerardinis RJ, Minna JD, Heymach JV.
    Cancer Res; 2019 Jul 01; 79(13):3251-3267. PubMed ID: 31040157
    [Abstract] [Full Text] [Related]

  • 4. Inhibitor of Differentiation-1 Sustains Mutant KRAS-Driven Progression, Maintenance, and Metastasis of Lung Adenocarcinoma via Regulation of a FOSL1 Network.
    Román M, López I, Guruceaga E, Baraibar I, Ecay M, Collantes M, Nadal E, Vallejo A, Cadenas S, Miguel ME, Jang JH, Martin-Uriz PS, Castro-Labrador L, Vilas-Zornoza A, Lara-Astiaso D, Ponz-Sarvise M, Rolfo C, Santos ES, Raez LE, Taverna S, Behrens C, Weder W, Wistuba II, Vicent S, Gil-Bazo I.
    Cancer Res; 2019 Feb 01; 79(3):625-638. PubMed ID: 30563891
    [Abstract] [Full Text] [Related]

  • 5. Blocking STAT3 by pyrvinium pamoate causes metabolic lethality in KRAS-mutant lung cancer.
    Feng J, Jiang W, Liu Y, Huang W, Hu K, Li K, Chen J, Ma C, Sun Z, Pang X.
    Biochem Pharmacol; 2020 Jul 01; 177():113960. PubMed ID: 32298693
    [Abstract] [Full Text] [Related]

  • 6. The outcomes of an impaired powerhouse in KRAS mutant lung adenocarcinoma cells by Elesclomol.
    Albayrak G, Korkmaz FD, Tozcu D, Dogan Turacli I.
    J Cell Biochem; 2019 Jun 01; 120(6):10564-10571. PubMed ID: 30628735
    [Abstract] [Full Text] [Related]

  • 7. Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation.
    Puyalto A, Rodríguez-Remírez M, López I, Macaya I, Guruceaga E, Olmedo M, Vilalta-Lacarra A, Welch C, Sandiego S, Vicent S, Valencia K, Calvo A, Pio R, Raez LE, Rolfo C, Ajona D, Gil-Bazo I.
    Mol Cancer; 2024 Apr 20; 23(1):78. PubMed ID: 38643157
    [Abstract] [Full Text] [Related]

  • 8. Oncogenic KRAS Sensitizes Lung Adenocarcinoma to GSK-J4-Induced Metabolic and Oxidative Stress.
    Hong BJ, Park WY, Kim HR, Moon JW, Lee HY, Park JH, Kim SK, Oh Y, Roe JS, Kim MY.
    Cancer Res; 2019 Nov 15; 79(22):5849-5859. PubMed ID: 31506334
    [Abstract] [Full Text] [Related]

  • 9. Cystine/glutamate antiporter xCT (SLC7A11) facilitates oncogenic RAS transformation by preserving intracellular redox balance.
    Lim JKM, Delaidelli A, Minaker SW, Zhang HF, Colovic M, Yang H, Negri GL, von Karstedt S, Lockwood WW, Schaffer P, Leprivier G, Sorensen PH.
    Proc Natl Acad Sci U S A; 2019 May 07; 116(19):9433-9442. PubMed ID: 31000598
    [Abstract] [Full Text] [Related]

  • 10. Nf1 loss promotes Kras-driven lung adenocarcinoma and results in Psat1-mediated glutamate dependence.
    Wang X, Min S, Liu H, Wu N, Liu X, Wang T, Li W, Shen Y, Wang H, Qian Z, Xu H, Zhao C, Chen Y.
    EMBO Mol Med; 2019 Jun 07; 11(6):. PubMed ID: 31036704
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Regulating autophagy facilitated therapeutic efficacy of the sonic Hedgehog pathway inhibition on lung adenocarcinoma through GLI2 suppression and ROS production.
    Fan J, Zhang X, Wang S, Chen W, Li Y, Zeng X, Wang Y, Luan J, Li L, Wang Z, Sun X, Shen B, Ju D.
    Cell Death Dis; 2019 Aug 19; 10(9):626. PubMed ID: 31427566
    [Abstract] [Full Text] [Related]

  • 13. Selective targeting of KRAS-driven lung tumorigenesis via unresolved ER stress.
    Shimomura I, Watanabe N, Yamamoto T, Kumazaki M, Tada Y, Tatsumi K, Ochiya T, Yamamoto Y.
    JCI Insight; 2021 Apr 08; 6(7):. PubMed ID: 33830081
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. SLC7A11 inhibits ferroptosis and downregulates PD-L1 levels in lung adenocarcinoma.
    Huang Z, Chen X, Wang Y, Yuan J, Li J, Hang W, Meng H.
    Front Immunol; 2024 Apr 08; 15():1372215. PubMed ID: 38655266
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.